AstraZeneca touts disease recurrence win, ‘strong trend’ in survival benefit for Imfinzi in early stomach cancer

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal.

When added to a chemotherapy combination called FLOT, Imfinzi significantly reduced the risk of disease recurrence, worsening or death in patients with resectable, early-stage gastric and gastroesophageal junction cancers who got the regimen before and after surgery, the company said Friday.